Merck Sharp Dohme Company Profile

What is the competitive landscape for MERCK SHARP DOHME

MERCK SHARP DOHME has twenty-two approved drugs.

There are seventeen US patents protecting MERCK SHARP DOHME drugs.

There are three hundred and eighty-eight patent family members on MERCK SHARP DOHME drugs in fifty-six countries and eighty-eight supplementary protection certificates in eighteen countries.

Summary for Merck Sharp Dohme

International Patents:	388
US Patents:	17
Tradenames:	18
Ingredients:	18
NDAs:	22

Drugs and US Patents for Merck Sharp Dohme

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	TEMODAR	temozolomide	CAPSULE;ORAL	021029-001	Aug 11, 1999		DISCN	Yes	No
Merck Sharp Dohme	PREVYMIS	letermovir	SOLUTION;INTRAVENOUS	209940-001	Nov 8, 2017		RX	Yes	Yes
Merck Sharp Dohme	CLARINEX	desloratadine	SOLUTION;ORAL	021300-001	Sep 1, 2004		DISCN	Yes	No
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes	9,908,845		Y	Y
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No	8,119,602

Expired US Patents for Merck Sharp Dohme

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	PREVYMIS	letermovir	TABLET;ORAL	209939-001	Nov 8, 2017	8,513,255
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001	6,337,090*PED
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	7,459,428
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-003	Oct 7, 2011	7,078,381
Merck Sharp Dohme	TEMODAR	temozolomide	POWDER;INTRAVENOUS	022277-001	Feb 27, 2009	8,623,868

Paragraph IV (Patent) Challenges for MERCK SHARP DOHME drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg		2006-06-21
	Tablets	25 mg, 50 mg and 100 mg		2010-10-18
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-25
	Oral Suspension	40 mg/mL		2011-02-28
	Injection	18 mg/mL, 16.7 mL vials		2015-11-24
	Orally Disintegrating Tablets	2.5 mg and 5 mg		2006-06-21
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-19
	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg		2012-11-06
	Capsules	140 mg and 180 mg		2008-03-24
	Delayed-release Tablets	100 mg		2014-06-16

International Patents for Merck Sharp Dohme Drugs

Country	Patent Number	Estimated Expiration
Mexico	2007015270
Malaysia	161834
Hungary	S1800028
South Korea	20200106100
South Korea	101016569

Supplementary Protection Certificates for Merck Sharp Dohme Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	300287	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER SITAGLIPTINE FOSFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070323
1084705	PA2014041	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-024, 2007 03 21 EU/1/07/382/001-024 20070321
1620113	122015000079	Germany		PRODUCT NAME: IVERMECTIN ZU SEINER VERWENDUNG FUER DIE BEHANDLUNG VON ROSAZEA; NAT. REGISTRATION NO/DATE: 92429.00.00 20150429; FIRST REGISTRATION: MALTA MA 117/01101 20150402
0720599	SPC/GB05/010	United Kingdom		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
3494972	2024C/522	Belgium		PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, MET INBEGRIP VAN DOLUTEGRAVIRNATRIUM, EN LAMIVUDINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1370 20190703

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Merck
• Merck And Co Inc
• Merck Kgaa
• Merck Sharp Dohme

Pharmaceutical Competitive Landscape Analysis: Merck Sharp & Dohme – Market Position, Strengths & Strategic Insights

In the ever-evolving world of pharmaceuticals, few names carry as much weight as Merck Sharp & Dohme (MSD). As we delve into the competitive landscape of this industry giant, we'll uncover the key factors that have propelled MSD to its current market position, explore its strengths, and gain valuable strategic insights. Let's embark on this journey through the pharmaceutical realm, where innovation meets business acumen.

The Pharmaceutical Titan: Merck Sharp & Dohme

Merck Sharp & Dohme, known as Merck & Co. in the United States and Canada, stands as a colossus in the global pharmaceutical industry. With a rich history dating back to 1891, MSD has consistently been at the forefront of medical innovation and scientific breakthroughs[4].

A Global Powerhouse

MSD's influence extends far beyond its New Jersey headquarters. The company operates in over 140 countries, leveraging its global footprint to maximize the reach of its products[5]. This international presence is crucial for tapping into emerging markets and ensuring sustainable growth.

"2023 was another very strong year for Merck. I am extremely pleased by the progress we've made to develop and deliver transformative therapies and vaccines that will help save and improve lives around the world. We reached more than 500 million people with our medicines last year alone, over half of which were donations, including through our program to treat river blindness," said Robert M. Davis, chairman and chief executive officer, Merck[1].

MSD's Market Position: A Force to Be Reckoned With

In the fiercely competitive pharmaceutical landscape, MSD has carved out a formidable position for itself. Let's examine the factors that contribute to its market standing.

Revenue and Rankings

As of 2024, MSD ranks fourth among global pharmaceutical companies, with human health division revenues totaling US$53.6 billion, up 3% from the previous year[7]. This impressive performance is a testament to the company's strong product portfolio and strategic focus on key therapeutic areas.

Key Therapeutic Areas

MSD's market position is bolstered by its strong presence in several critical therapeutic areas:

1. Oncology
2. Vaccines
3. Infectious diseases
4. Cardio-metabolic disorders
5. Immunology

The company's diverse portfolio allows it to cater to a wide range of healthcare needs, further solidifying its market position[5].

Strengths That Set MSD Apart

MSD's success isn't accidental. It's the result of several key strengths that give the company a competitive edge in the pharmaceutical industry.

1. Robust Research and Development

At the heart of MSD's success lies its unwavering commitment to research and development (R&D). In 2023, the company invested a staggering $30.5 billion in R&D, including expenditures related to certain business development transactions[2]. This substantial investment fuels innovation and helps maintain MSD's pipeline of promising new treatments.

2. Blockbuster Products

MSD's portfolio includes several blockbuster products that generate significant revenue. The standout performer is Keytruda, an immunotherapy drug that accounted for over 46% of the company's pharmaceutical revenues in 2023, with sales reaching US$25 billion[7].

3. Strong Vaccine Division

MSD's vaccine division is another pillar of strength. Products like Gardasil (HPV vaccine) have shown impressive growth, with sales increasing by 29% in 2023[7].

4. Global Reach and Distribution Network

The company's extensive global presence allows it to reach diverse markets and adapt to regional healthcare needs. This global footprint is a significant asset in an increasingly interconnected world[5].

5. Strategic Partnerships and Collaborations

MSD actively seeks partnerships with academic institutions, biotech firms, and other pharmaceutical companies. These collaborations enhance the company's R&D capabilities and help accelerate the development of new treatments[3].

Strategic Insights: Navigating the Future

As we look towards the future, several strategic insights emerge that will likely shape MSD's trajectory in the coming years.

Diversification Beyond Keytruda

While Keytruda has been a phenomenal success, MSD is keenly aware of the need to diversify its revenue streams. The drug is set to lose market exclusivity in 2028, prompting the company to explore new avenues for growth[7].

Focus on Emerging Markets

Expanding into emerging markets presents a significant opportunity for MSD. These markets often have growing healthcare needs and increasing access to medical treatments, providing fertile ground for expansion.

Embracing Biotechnology

The future of pharmaceuticals is increasingly intertwined with biotechnology. MSD's investments and partnerships in this area suggest a strategic focus on staying at the cutting edge of biotech innovations.

Addressing Global Health Challenges

MSD's commitment to addressing global health challenges, as evidenced by its donations and programs like the one treating river blindness, not only serves a humanitarian purpose but also enhances the company's reputation and global influence[1].

Competitive Landscape: MSD's Rivals

To fully appreciate MSD's position, we must consider its main competitors in the pharmaceutical industry.

1. Pfizer

Pfizer, the industry leader, is known for its extensive portfolio of medicines, vaccines, and consumer healthcare products. Its recent success with the COVID-19 vaccine has further strengthened its market position[5].

2. Johnson & Johnson

Johnson & Johnson's pharmaceutical division, Janssen, develops drugs across various therapeutic areas, making it a significant competitor to MSD[5].

3. Novartis

Novartis focuses on innovative medicines, generics, and eye care products. The company's strong R&D pipeline and strategic acquisitions position it as a key player in the industry[5].

4. Roche

Roche is a global leader in biotechnology and pharmaceuticals, with a strong focus on oncology, immunology, infectious diseases, ophthalmology, and neuroscience[5].

Future Outlook: MSD's Path Forward

As we look to the future, MSD appears well-positioned to maintain its strong market presence. The company's 2025 financial outlook anticipates worldwide sales to be between $64.1 billion and $65.6 billion, reflecting confidence in continued growth[10].

Promising Pipeline

MSD's pipeline remains robust, with several promising candidates in late-stage development. The company initiated more than 20 Phase 3 study starts in 2023, including the progression of eight novel assets into Phase 3[1].

Strategic Acquisitions and Partnerships

MSD continues to augment its pipeline through strategic acquisitions and partnerships. Recent examples include the acquisition of Prometheus and Imago, and collaboration agreements with Daiichi Sankyo and Kelun-Biotech[1].

Key Takeaways

1. MSD maintains a strong market position, ranking fourth among global pharmaceutical companies with revenues of $53.6 billion in 2023.
2. The company's success is driven by its robust R&D investments, blockbuster products like Keytruda, and a strong vaccine division.
3. MSD's global presence and strategic partnerships contribute significantly to its competitive advantage.
4. The company is actively diversifying beyond Keytruda and focusing on emerging markets and biotechnology to drive future growth.
5. MSD's commitment to addressing global health challenges enhances its reputation and influence in the industry.
6. With a promising pipeline and strategic acquisitions, MSD is well-positioned for continued growth in the coming years.

FAQs

1. What is MSD's most successful product? Keytruda, an immunotherapy drug, is currently MSD's most successful product, accounting for over 46% of the company's pharmaceutical revenues in 2023.

2. How much does MSD invest in research and development? In 2023, MSD invested approximately $30.5 billion in research and development, including expenditures related to certain business development transactions.

3. What are MSD's key therapeutic areas? MSD focuses on several key therapeutic areas, including oncology, vaccines, infectious diseases, cardio-metabolic disorders, and immunology.

4. How is MSD preparing for the loss of market exclusivity for Keytruda? MSD is diversifying its portfolio through strategic acquisitions, partnerships, and investments in R&D to develop new innovative treatments across various therapeutic areas.

5. What is MSD's global market presence? MSD operates in over 140 countries, leveraging its global footprint to maximize the reach of its products and tap into emerging markets.

Sources cited: [1] https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/ [2] https://www.merck.com/news/merck-reports-strong-momentum-in-expanding-and-enabling-access-to-health-care-driving-sustainability-and-operating-responsibly-in-2023-2024-impact-report/ [3] https://blog.osum.com/merck-swot-analysis/ [4] https://en.wikipedia.org/wiki/Merck_&_Co. [5] https://pitchgrade.com/companies/merck-co [7] https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2024 [10] https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/

Last updated: 2025-02-12